Relmada Therapeutics
RLMD
85 hedge funds and large institutions have $316M invested in Relmada Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 6 closing their positions.
137% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $5.65M
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
4% more funds holding
Funds holding: 82 → 85 (+3)
2.26% more ownership
Funds ownership: 56.93% → 59.19% (+2.3%)
6% less capital invested
Capital invested by funds: $335M → $316M (-$18.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
VA
VR Adviser
New York
|
+$18.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.73M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$2.66M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.63M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$20.5M |
| 2 |
CC
Commodore Capital
New York
|
-$5.69M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.47M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.03M |
| 5 |
BlackRock
New York
|
-$628K |
RLMD Hedge Fund Activity: Q2 2021 in Review
85 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2021, worth a combined $316M — down 5.6% from $335M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RLMD positions and 6 closed out — a net gain of 3 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was VR Adviser, adding an estimated $18.6M. The largest seller was Avoro Capital Advisors, cutting an estimated $20.5M.
- 85 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2021, up from 82 in Q1 2021.
- Funds reported $316M of Relmada Therapeutics stock for Q2 2021, down 5.6% quarter-over-quarter.
- 9 funds opened new Relmada Therapeutics positions in Q2 2021 and 6 closed out, a net change of +3 holders.
- The largest Relmada Therapeutics buyer in Q2 2021 was VR Adviser, an estimated $18.6M added.
- The largest Relmada Therapeutics seller in Q2 2021 was Avoro Capital Advisors, an estimated $20.5M sold.
Based on aggregated 13F filings for Q2 2021.